Navigation Links
Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment

A new drug called febuxostat has been found to reduce plasma levels of uric acid more effectively in Gout than the currently used drug allopurinol. If the results of the clinical trial are successful//, then it would mean the end of a 40 year search for successful treatment of Gout.

Gout is characterized by accumulation and deposition of needle shaped uric acid crystals in the joints, thereby leading to inflammation and pain. Progressively, it leads to a condition called ‘Gouty arthritis’ and is associated by a significant reduction in joint mobility.

The only existing standard treatment for Gout is administration of allopurinol, which reduces the levels of uric acid production by blocking certain key steps in uric acid synthesis. In addition, it also decreases the plasma levels of uric acid over a period of time.

The study was conducted amongst a group of 762 patients, diagnosed to suffer from Gout and is believed to be the largest clinical trial ever done on patients with Gout. The mechanism of action of Febuxostat is very similar to allopurinol.

The study participants were either given allopurinol or febuxostat (two different doses) as a form of treatment, the goal of which was to reduce plasma uric acid levels by as much as 6 mg/dl. Allopurinol treatment was taken by 21% of the members, followed by 53 and 62% who took 80 and 120mg of febuxostat respectively.

At the end of the study, it was found that the new drug was more effective than allopurinol when used for more than a year, as revealed by statistical tests. However, a large number of patients were found to discontinue from the study due to the high incidence of adverse effects. The main site of drug metabolism is the liver which facilitates administration of the drug to patients with compromised kidney function as well.

The drug has not yet been approved by the U.S. Food and Drug Administration agency (FDA) for therapeutic use. More studies are clearly indicated to determine the long term clinical benefits of the new drug, taking into critical consideration the safety.
'"/>




Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Renal Trails Do Not Have Sufficient Women Participants
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... On Dec. ... the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have ... (MPNs) by going above and beyond the standard of care, demonstrating leadership within the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... the launch of its 60-day free trial program for all of the company’s ... the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of ... of an injury, patients must find the one that works for them. When an ... created a machine that worked and decided to share it with others. , He ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016  The Addiction Treatment ... Academy of Managed Care Pharmacy (AMCP), has released ... better address the opioid addiction crisis, including through ... (MAT). ATAG,s newly released paper, "The ... to Naloxone," addresses many issues around gaps and ...
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
(Date:12/2/2016)... Dec. 2, 2016   CytoSorbents Corporation (NASDAQ: ... its European Union approved CytoSorb ® cytokine adsorber ... patients worldwide, announced that Dr. Phillip Chan , ... Annual LD Micro Main Event investor conference held ... the Luxe Sunset Boulevard Hotel in Los ...
Breaking Medicine Technology: